Nexus Surgical and Medicare Ltd Upgraded to Hold on Technical and Financial Improvements

Technical Trends Signal Renewed Momentum

The primary catalyst for the upgrade stems from a marked improvement in the company’s technical profile. The technical grade shifted from mildly bullish to bullish, driven by several key indicators. On a weekly basis, the Moving Average Convergence Divergence (MACD) remains mildly bearish, but the monthly MACD has turned bullish, suggesting strengthening momentum over the longer term. Meanwhile, Bollinger Bands readings are bullish on both weekly and monthly charts, indicating increased price volatility with an upward bias.

Daily moving averages have also turned bullish, reinforcing short-term positive momentum. The Know Sure Thing (KST) indicator is bullish on a weekly basis, though mildly bearish monthly readings temper enthusiasm slightly. Relative Strength Index (RSI) readings on both weekly and monthly scales show no clear signal, while Dow Theory trends remain neutral. Overall, the technical landscape points to a more constructive price action environment, supporting the upgrade decision.

Financial Trend: Robust Quarterly Performance

Financially, Nexus Surgical has demonstrated solid performance in the latest quarter (Q4 FY25-26). Net sales for the nine-month period ending March 2026 rose to ₹6.15 crores, while Profit Before Depreciation, Interest and Taxes (PBDIT) for the quarter reached a peak of ₹0.30 crores. Profit Before Tax excluding other income (PBT less OI) also hit a quarterly high of ₹0.30 crores, underscoring operational efficiency and improved profitability.

The company’s average Return on Equity (ROE) stands at an impressive 31.15%, with the most recent annual figure at 40.6%. This level of profitability is a strong indicator of management’s ability to generate returns on shareholder capital, a key factor in the quality assessment. Additionally, Nexus Surgical has consistently outperformed the BSE500 index over the past three years, delivering a 16.80% return in the last year alone compared to the index’s negative 5.98% return.

Quality Assessment: Strong Fundamentals Amid Micro-Cap Status

Nexus Surgical’s quality rating remains solid, supported by its consistent financial returns and operational metrics. Despite being classified as a micro-cap stock, the company’s fundamentals are robust, with a track record of steady profitability and shareholder value creation. The majority of shares are held by non-institutional investors, which may reflect retail confidence but also suggests limited institutional backing.

The company’s long-term return profile is particularly noteworthy, with a 5-year return of 535.56% vastly outperforming the Sensex’s 44.51% over the same period. However, the 10-year return is negative at -59.92%, indicating some volatility and challenges in earlier years. This mixed long-term performance underscores the importance of recent improvements in both financial and technical parameters.

Valuation: Expensive Yet Discounted Relative to Peers

Valuation remains a nuanced factor in the rating change. Nexus Surgical trades at a Price to Book (P/B) ratio of 6.1, which is considered very expensive relative to typical NBFC valuations. This high P/B is driven by the company’s strong ROE of 40.6%, which justifies a premium to some extent. However, when compared to its peers’ historical valuations, the stock is trading at a discount, suggesting some relative value remains.

Profit growth over the past year has been robust at 23%, while the stock’s price return was 16.80%, resulting in a low Price/Earnings to Growth (PEG) ratio of 0.3. This low PEG ratio indicates that the stock’s earnings growth is not fully reflected in its price, supporting the Hold rating rather than a Sell or Buy. Investors should weigh the premium valuation against the company’s growth prospects and financial strength.

Market Performance and Price Action

On 16 June 2026, Nexus Surgical’s stock closed at ₹20.02, up 2.09% from the previous close of ₹19.61. The stock’s 52-week high stands at ₹25.50, with a low of ₹13.26, indicating a wide trading range and potential for volatility. Short-term returns have been mixed, with a 1-week gain of 2.56% lagging the Sensex’s 3.73%, and a 1-month decline of 8.50% contrasting with the Sensex’s 1.36% rise. However, year-to-date and 1-year returns remain strong at 14.40% and 16.80% respectively, outperforming the broader market indices.

Conclusion: A Balanced Hold Rating Reflecting Mixed Signals

The upgrade of Nexus Surgical and Medicare Ltd’s investment rating from Sell to Hold reflects a balanced assessment of its current standing. Improvements in technical indicators, particularly the shift to a bullish trend, have been pivotal. Financially, the company’s strong quarterly results and high ROE underpin its quality credentials, while valuation metrics suggest the stock is expensive but not excessively so relative to peers.

Investors should note the stock’s micro-cap status and the inherent volatility that accompanies it. While the company has outperformed major indices over recent years, the mixed long-term returns and premium valuation warrant caution. The Hold rating signals that the stock is fairly valued at present, with potential upside contingent on sustained financial performance and continued positive technical momentum.

For those seeking exposure to the NBFC sector with a focus on quality and growth, Nexus Surgical represents a viable option, albeit with measured expectations. Monitoring upcoming quarterly results and technical developments will be crucial for reassessing the stock’s outlook in the near term.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →